Management of Reticulonodular Lesions in the Lungs

Initial Assessment

The management of reticulonodular lesions in the lungs should follow a risk-stratified approach based on nodule size, characteristics, and patient risk factors, with nodules ≥8 mm or ≥300 mm³ requiring risk assessment using validated prediction models to guide further evaluation, as recommended by the American College of Radiology 1
All CT scans of the thorax should be reconstructed with contiguous thin sections (≤1.5 mm, typically 1.0 mm) to enable accurate characterization and measurement of pulmonary nodules, according to the Radiological Society of North America 2
Coronal and sagittal reconstructions should be routinely acquired to facilitate distinction between nodules and scars, as suggested by the Radiological Society of North America 2
Nodules with diffuse, central, laminated or popcorn pattern of calcification or macroscopic fat do not require follow-up or further investigation, as stated by the British Thoracic Society 3, 1
Typical perifissural or subpleural nodules (homogeneous, smooth, solid nodules with lentiform or triangular shape within 1 cm of a fissure or pleural surface and <10 mm) do not require follow-up, according to the British Thoracic Society 3, 1
Nodules <5 mm in maximum diameter or <80 mm³ in volume do not require follow-up, as recommended by the British Thoracic Society 3, 4, 1

Use the Brock model (full, with spiculation) for initial risk assessment, especially in smokers or former smokers aged ≥50, as suggested by the British Thoracic Society 3, 1
Consider key clinical risk factors including increasing age (OR=1.04–2.2 for every 10-year increment), current or former smoking status (OR=2.2–7.9), pack-years of smoking, and previous history of extrapulmonary cancer, as stated by the British Thoracic Society 5
Important radiological risk factors include nodule diameter (OR approximately 1.1 for each 1 mm increment), spiculation (OR=2.1–5.7), upper lobe location, pleural indentation, and volume doubling time <400 days, as reported by the British Thoracic Society 5

For solid nodules with low risk (<10% probability of malignancy), CT surveillance is recommended, with follow-up at 1 year for nodules 5-6 mm and at 3 months and 1 year for nodules ≥6 mm, as suggested by the British Thoracic Society 3, 1, 7
For solid nodules with intermediate risk (10-70% probability of malignancy), PET-CT is recommended for further risk assessment, and consider image-guided biopsy if PET-CT is positive or inconclusive, as stated by the British Thoracic Society 3, 6, 1
For solid nodules with high risk (>70% probability of malignancy), consider excision or non-surgical treatment, with surgical resection preferentially by video-assisted thoracoscopic surgery (VATS), as recommended by the British Thoracic Society 3, 6, 1

PET-CT has approximately 97% sensitivity and 78% specificity for nodules ≥1 cm, but limitations include false-negatives and false-positives, as reported by the American College of Radiology 1
Image-guided biopsy should be considered for nodules where the result will alter management plan, with awareness of the risk of pneumothorax, as stated by the British Thoracic Society 6, 1
Bronchoscopy should be considered in the evaluation of pulmonary nodules with bronchus sign present on CT, with augmentation of yield using radial endobronchial ultrasound, fluoroscopy, or electromagnetic navigation, as suggested by the British Thoracic Society 6

Do not assume coexistent lung nodules in patients with known lung cancer are metastases; evaluate them in their own right, as recommended by the British Thoracic Society 3
Do not use partial thoracic CT scans for nodule follow-up, as this may miss unanticipated abnormal findings, as stated by the Radiological Society of North America 8
Do not rely solely on manual caliper measurements; volumetric assessment is more accurate for detecting growth, as reported by the British Thoracic Society 4
Be aware that the negative predictive value of a biopsy is greatest when the pre-test probability of malignancy is low, as stated by the National Comprehensive Cancer Network 9